Letrozole (brand name Letroxyl) is an oral non-steroidal aromatase inhibitor that has been introduced for the adjuvant treatment of hormonally-responsive carcinoma. Estrogens are made by the conversion of androgens through the activity of the aromatase accelerator. Letrozole blocks production of estrogens during this means by competitive, reversible binding to the protoheme of its haemoprotein P450 unit. The action is particular, and letrozole doesn’t cut back production of mineralo- or corticosteroids. In distinction, the antiestrogenic action of antagonist, the main medical medical aid before the arrival of aromatase inhibitors, is owing to its interfering with the steroid hormone receptor, instead of inhibiting estrogen production.
Commercial Names: Mamazol, Letroz, Letrazole, Feofar, Letronat, Fematroz, Letzol, Lets, Fempro, Shantroz, Zaronil, Momazol, Letoval, Trozet, Letrova, Letrozol, Letoripe, Letroxyl, Letocor, Femara, Oreta, Oncolet, Feofer, Letromina, Letz.